Medulloblastoma other diagnostic studies

Jump to: navigation, search

Medulloblastoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Medulloblastoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Medulloblastoma other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Medulloblastoma other diagnostic studies

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Medulloblastoma other diagnostic studies

CDC on Medulloblastoma other diagnostic studies

Medulloblastoma other diagnostic studies in the news

Blogs on Medulloblastoma other diagnostic studies

Directions to Hospitals Treating Medulloblastoma

Risk calculators and risk factors for Medulloblastoma other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]

Overview

Bromodeoxyuridine labeling study may be helpful in the diagnosis of medulloblastoma. An elevated bromodeoxyuridine labeling index is suggestive of a rapid growth rate of medulloblastoma.[1]

Bromodeoxyuridine Labeling Study

  • Bromodeoxyuridine labeling study may be helpful in the diagnosis of medullblastoma. An elevated bromodeoxyuridine labeling index is suggestive of a rapid growth rate of medulloblastoma.[1]
  • The bromodeoxyuridine labeling index of medulloblastoma is measured between:

References

  1. 1.0 1.1 Onda K, Davis RL, Edwards MS (1996). "Comparison of bromodeoxyuridine uptake and MIB 1 immunoreactivity in medulloblastomas determined with single and double immunohistochemical staining methods". J Neurooncol. 29 (2): 129–36. PMID 8858517.

Linked-in.jpg